Since the immediate emergency posed by the pandemic in 2020, the PHOSP-COVID team have recruited more than 7,000 participants from 83 hospitals, obtaining 16 million data points and collecting more than 100,000 samples.
The resulting research, of which many papers have been published in the last 12 months, has highlighted large ongoing health impairments and provided insight into the possible biological mechanisms underpinning long-COVID, informing further research into potential treatments and patient care.
Two clinical trials of treatments for long-COVID are now underway. The first, PHOSP-R is a rehabilitation trial, which was completed in Spring 2024 and findings submitted for publication. In the second trial which commenced in April 2024, inflammatory long-COVID participants are taking part in a phase IIa double blind, randomised placebo-controlled trial of Tocilizumab to investigate the effect on health-related quality of life in adults with Long COVID and persistent inflammation (PHOSP-I) trial.
Working groups across all areas of physiology, including mental health and rehabilitation, with input from patient and charity groups has enabled a multimodal and holistic study of what continues to be a significant health burden on the population into 2024.
Related news stories
- Long-term cognitive and psychiatric effects of COVID-19 revealed in new study
- Leicester team behind major study into the long-term impacts of COVID-19 is highly commended
- Study seeking to find first medication for Long COVID welcomes first participant
- Leicester-led study finds long-COVID leaves tell-tale traces in the blood
- Longer-term organ abnormalities confirmed in some post-hospitalised COVID patients
- Blood clots during COVID-19 may be a cause of ongoing cognitive problems
- Study reveals extent of residual lung damage after COVID-19 hospitalisation
Case study added August 2024